Beam Therapeutics Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for BEAM, updated each market day.
BEAM AI Sentiment
AI sees no strong directional signal for Beam Therapeutics Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Beam Therapeutics Inc. Common Stock
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Sector
Exchange
Market Cap
$2,681,874,930
Cap Tier
Employees
511
Headquarters
CAMBRIDGE, MA
Listed Since
Feb. 6, 2020
Website
BEAM Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
BEAM Volatility
Beam Therapeutics Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
